Latest News and Press Releases

GAITHERSBURG, Md., Oct. 18, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced the pricing of an underwritten public offering of approximately 2.2 million shares of its common stock...

GAITHERSBURG, Md., Oct. 17, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being...

GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today provided an update on its commercial activities and clinical trials for its Acuitas® AMR Gene Panel tests and...

GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that Evan Jones, Chairman and Chief Executive Officer, will present a corporate overview at two...

GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today a groundbreaking collaboration with the New York State Department of Health (“DOH”) and ILÚM Health...

GAITHERSBURG, Md., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that Evan Jones, Chairman and Chief Executive Officer, will present a corporate overview at the 20th...

Revenue increases 12% to $0.8 million, net loss narrows 21% to $3.3 million Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Aug. 02, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc....

GAITHERSBERG, Md., July 25, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that the Company will report financial results for the three and six months ended June 30, 2018 after...

GAITHERSBERG, Md., June 14, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has negotiated modifications related to its $1,000,000 Second Amended and Restated Senior...

90% accuracy data presented for rapid antibiotic resistance prediction using Acuitas AMR Gene Panel and Acuitas Lighthouse on urine clinical specimens Prospective clinical trial in Colombia...